Ryan Scott

Articles

Novel Combinations Seek to Build Off Lenalidomide/Rituximab Backbone in Indolent Lymphoma

September 25th 2023

Paolo Strati, MD, discusses novel combinations for the treatment of indolent B-cell lymphoma, emphasizes the primary goal of improving the efficacy of immunotherapy and providing patients with chemotherapy-free treatment options, and highlights ongoing trials are investigating various approaches to enhance the activity of lenalidomide/rituximab

Novel Targets Could Expand CAR T-Cell Therapy and Bispecific Antibody Options in Myeloma

September 22nd 2023

Ajai Chari, MD, discusses selecting between CAR T-cell therapies and bispecific antibodies in multiple myeloma, expands on the factors that can help inform these decisions, and highlights the need for additional data to help inform sequencing and potential combinations for these therapies.

Triplets With Azacitidine/Venetoclax Aim to Improve Responses in AML

September 21st 2023

Courtney D. DiNardo, MD, MSCE, discusses ongoing investigations of triplet regimens with an azacitidine/venetoclax backbone for the treatment of patients acute myeloid leukemia and highlights the unmet needs that remain in older and high-risk subgroups within this patient population.

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

September 20th 2023

Second-line treatment with regorafenib displayed safety in patients with advanced hepatocellular carcinoma who were not eligible for treatment on the phase 3 RESORCE trial, according to data from the phase 2 REGAIN trial.

Ongoing Research Aims to Address Further Questions on Fixed-Duration Therapy in CLL

September 20th 2023

Alessandra Ferrajoli, MD, discusses the continued investigation of fixed-duration therapy as a frontline approach for patients with CLL, highlights both the pros and cons of this strategy, and touches on the unanswered questions regarding fixed-duration therapy that ongoing research aims to address.

Continued Research Underscores the Need to Explore New Approaches Across the Breast Cancer Armamentarium

September 15th 2023

Stephanie L. Graff, MD, expands on treatment options available for patients with premenopausal breast cancer who are trying to conceive, highlighting the POSITIVE trial in women with endocrine-responsive breast cancer.

Ongoing Trials Could Shift BTK Inhibitors to Earlier Settings in MCL

September 14th 2023

Brad S. Kahl, MD, discusses the evolving role of BTK inhibitors in the treatment of patients with mantle cell lymphoma, expands on key ongoing trials investigating these agents in earlier settings and in different combinations, and expands on what the addition of pirtobrutinib to the treatment arsenal has meant for this population.

Real-World Analysis Highlights US Treatment Patterns for Frontline Atezolizumab/Bevacizumab in HCC

September 12th 2023

Real-world data from a systemic review of treatment patterns in the United States showed that the majority of patients with hepatocellular carcinoma administered atezolizumab and bevacizumab in the frontline setting discontinued treatment within 12 months, indicating the need for additional research on the effectiveness of this regimen for patients with high-risk disease.

Data for Second-Line or Later Ramucirumab Show Consistent Benefit in Advanced HCC

September 12th 2023

Treatment with ramucirumab in the second line after first-line lenvatinib monotherapy or the combination of atezolizumab and bevacizumab, or as third-line treatment following both regimens, elicited efficacy comparable with second-line ramucirumab following treatment with sorafenib in patients with advanced hepatocellular carcinoma.

Baseline Characteristics Not Tied to Benefit With Durvalumab/Tremelimumab and Chemo in Metastatic NSCLC

September 11th 2023

Treatment with durvalumab plus tremelimumab and chemotherapy led to higher rates of long-term clinical benefit compared with chemotherapy alone in the treatment of patients with first-line metastatic non–small cell lung cancer.

TNO155/JDQ433 Combo Elicits Responses, Is Tolerable in KRAS G12C+ Solid Tumors

September 10th 2023

The combination of the SHP2 inhibitor TNO155 and the KRAS G12C inhibitor JDQ433 showed antitumor activity in patients with KRAS G12C-mutated solid tumors, including non–small cell lung cancer, irrespective of prior treatment with a KRAS G12C inhibitor.

Pirtobrutinib, Liso-Cel Could Expand Treatment Arsenal for Relapsed/Refractory CLL

September 5th 2023

Mazyar Shadman, MD, MPH, discusses the evolution of BTK inhibitors in CLL, highlights how treatment patterns have evolved with the continued emergence of data on ibrutinib, acalabrutinib, and zanubrutinib, and expands on how pirtobrutinib and liso-cel could address unmet needs for this patient population.

PRGN-2009 Plus Bintrafusp Alfa Shows Early Activity in HPV-Associated Malignancies

September 3rd 2023

James L. Gulley, MD, PhD, reviews the safety and efficacy of PRGN-2009 alone and in combination with bintrafusp alfa in HPV-associated cancers and explains how this kind of approach may address an unmet clinical need.

Retrospective Data Show Aggressive Axillary Surgery Is Not Associated With Improved Outcomes in Select Patients With Breast Cancer

September 2nd 2023

Raymond Mailhot Vega, MD, MPH, delves into the rationale for exploring the outcomes of patients who underwent axillary surgery or sentinel lymph node biopsy, explained the implications of these findings, and detailed what eventual data from the phase 3 Alliance A011202 could mean for the breast cancer treatment paradigm.

Momelotinib Could Represent Pivotal New Treatment Option in Myelofibrosis

September 1st 2023

Aaron T. Gerds, MD, PhD, expands on the potential role of momelotinib in the treatment of patients with myelofibrosis who present with anemia, details the data from MOMENTUM, and explains what FDA approval of momelotinib could mean for the treatment of this patient population.

Dendritic Cell Vaccines Represent Potential Avenue to Enhance Immunotherapy in Ovarian Cancer

September 1st 2023

Martin Cannon, PhD, delves into ongoing research on the use of dendritic cell vaccines to generate Th17 responses in patients with ovarian cancer and details how this could address a need for select patients with ovarian cancer.

Cracking the Immunotherapy Code Remains a Challenge in Ovarian Cancer

August 31st 2023

Martin Cannon, PhD, details the history of investigating immune checkpoint inhibitors in patients with ovarian cancer and expands on the questions that need to be answered to potentially improve the activity of these agents in this patient population.

Treatment Sequencing in Refractory Urothelial Carcinoma Requires a Personalized Approach

August 30th 2023

Jue Wang, MD, highlights key takeaways regarding treatment sequencing for patients with relapsed/refractory urothelial carcinoma and the key factors that could help inform decisions for individual patients.

Radical Cystectomy or Bladder Preservation: Understanding Optimal Therapy for Locally Advanced Bladder Cancer

August 28th 2023

Neil Desai, MD, MHS, expands on the need for further research regarding potential treatment strategies for patients with locally advanced, nonmetastatic muscle-invasive bladder cancer who may not benefit from standard approaches.

Rural Patient Populations at Higher Risk of Lung Cancer Mortality

August 25th 2023

Logan Roof, MD, discusses the importance of investigating demographic disparities that exist in lung cancer mortality, expands on the results of the population-based CDC database analysis, and discusses potential next steps to address these disparities in the future.